| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, University of Calgary, Calgary, Alberta, Canada T2N 4N1
Glycosaminoglycan (GAG) synthesis of B-16 melanoma metastatic variants was examined in vivo and in vitro to begin to assess the relationship between the presence of these polymers and the process of primary invasion and metastasis. The variants that were examined for GAG production included the F-1 line that exhibits low metastatic potential, the F-10 line selected for high metastatic potential, and the BL6 line selected for high invasiveness. The F-1 cell line was routinely less invasive than the F-10 and BL6 lines when injected s.c. into the legs of irradiated Swiss Webster mice. All cell lines formed palpable tumors after s.c. injection, but histological sections revealed early and extensive invasion in only F-10 and BL6 tumors. The F-1 tumors were surrounded by a connective tissue capsule and did not begin to invade into host tissue until this structure disappeared approximately 16 days after injection of tumor cells. Some consistent alterations in GAG synthesis, particularly the release of hyaluronic acid and heparan sulfate, were observed among the cell lines in vivo and in vitro, although differences observed in vitro were small and variable. In vivo all tumors were surrounded by a hyaluronic acid-rich zone that was concentrated at the tumor-stromal interface and was transitory. Hyaluronate occurred as a diffuse band around BL6 and F-10 tumors but was confined to a capsule surrounding the less aggressive F-1 tumor. In vitro the BL6 and F-10 cell lines released larger amounts of heparan sulfate and hyaluronic acid than did the F-1 cell line. Differences in release of chondroitin sulfate by the cell lines were not observed. Differences in trypsin-releasable GAG, presumably associated with the glycocalyx, were also not apparent. These results link the release in vitro and organization in vivo of hyaluronic acid and heparan sulfate to invasion and metastasis.
1 Recipient of a grant from the National Institute of Canada and a National Institute of Canada Scholarship career award. To whom requests for reprints should be addressed.
Received 3/21/84. Revised 6/10/85. Accepted 6/19/85.
This article has been cited by other articles:
|
|
 |
|
  K. Hosono, Y. Nishida, W. Knudson, C. B. Knudson, T. Naruse, Y. Suzuki, and N. Ishiguro Hyaluronan Oligosaccharides Inhibit Tumorigenicity of Osteosarcoma Cell Lines MG-63 and LM-8 in Vitro and in Vivo via Perturbation of Hyaluronan-Rich Pericellular Matrix of the Cells Am. J. Pathol., July 1, 2007; 171(1): 274 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Itano, T. Sawai, F. Atsumi, O. Miyaishi, S. Taniguchi, R. Kannagi, M. Hamaguchi, and K. Kimata Selective Expression and Functional Characteristics of Three Mammalian Hyaluronan Synthases in Oncogenic Malignant Transformation J. Biol. Chem., April 30, 2004; 279(18): 18679 - 18687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Itano, F. Atsumi, T. Sawai, Y. Yamada, O. Miyaishi, T. Senga, M. Hamaguchi, and K. Kimata Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration PNAS, March 19, 2002; 99(6): 3609 - 3614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Touab, J. Villena, C. Barranco, M. Arumi-Uria, and A. Bassols Versican Is Differentially Expressed in Human Melanoma and May Play a Role in Tumor Development Am. J. Pathol., February 1, 2002; 160(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Anttila, R. H. Tammi, M. I. Tammi, K. J. Syrjänen, S. V. Saarikoski, and V.-M. Kosma High Levels of Stromal Hyaluronan Predict Poor Disease Outcome in Epithelial Ovarian Cancer Cancer Res., January 1, 2000; 60(1): 150 - 155. [Abstract] [Full Text]
|
|
|
|
|
|
N. Itano, T. Sawai, O. Miyaishi, and K. Kimata Relationship between Hyaluronan Production and Metastatic Potential of Mouse Mammary Carcinoma Cells Cancer Res., May 1, 1999; 59(10): 2499 - 2504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kayastha, A. N., F. M., S. Piver, J. Mukkamalla, M. Romero-Guittierez, and B. A. Werness Expression of the Hyaluronan Receptor, CD44S, in Epithelial Ovarian Cancer Is an Independent Predictor of Survival Clin. Cancer Res., May 1, 1999; 5(5): 1073 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kosaki, K. Watanabe, and Y. Yamaguchi Overproduction of Hyaluronan by Expression of the Hyaluronan Synthase Has2 Enhances Anchorage-independent Growth and Tumorigenicity Cancer Res., March 1, 1999; 59(5): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Ellis, J Banyard, and S. Schor Differential response of fetal and adult fibroblasts to cytokines: cell migration and hyaluronan synthesis Development, January 4, 1997; 124(8): 1593 - 1600. [Abstract] [PDF]
|
|
|
|
 |
|
 M Goebeler, D Kaufmann, E. Brocker, and C. Klein Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors J. Cell Sci., January 7, 1996; 109(7): 1957 - 1964. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Simpson, J. Reiland, S. R. Burger, L. T. Furcht, A. P. Spicer, T. R. Oegema Jr., and J. B. McCarthy Hyaluronan Synthase Elevation in Metastatic Prostate Carcinoma Cells Correlates with Hyaluronan Surface Retention, a Prerequisite for Rapid Adhesion to Bone Marrow Endothelial Cells J. Biol. Chem., May 18, 2001; 276(21): 17949 - 17957. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
